SCN1A variations and response to multiple antiepileptic drugs

Pharmacogenomics Journal

Volumn 14, Issue 4, 2014, Pages 385-389

  Yip, T S C ^a   O'Doherty, C ^a   Tan, N C K ^b   Dibbens, L M ^a   Suppiah, V ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

epilepsy; pharmacogenetics; SCN1A

Indexed keywords

ANTICONVULSIVE AGENT; GENOMIC DNA; SODIUM CHANNEL NAV1.1; SODIUM CHANNEL NAV1.7; SCN1A PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CAUCASIAN; CHILD; COHORT ANALYSIS; EPILEPSY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE TRAIT; SCN1A GENE; SCN7A GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETICS; INFANT; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84905000243     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.43     Document Type: Article

References (36)

1. World Health Organization. Atlas: epilepsy care in the world. World Health Organization: Geneva, 2005, Available at http://www.who.int/mental- health/neurology/epilepsy-atlas-introdion.pdf. Accessed on July 2013.
2. Walley N, Sisodiya SM, Goldstein DB. Pharmacogenetics and pharmacogenomics. In: Engel Jr J, Pedley TA (eds). Epilepsy: A Comprehensive Textbook. 2nd edn. Lippincott Williams & Wilkins: Philadelphia, 2008.
3. Loescher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmaco-genetics on the treatment of epilepsy. Epilepsia 2009; 50: 1-23.
4. Depondt C. Pharmacogenetics in epilepsy treatment: sense or nonsense? Pers Med 2008; 5: 123-131.
5. Hollingworth SA, Eadie MJ. Antiepileptic drugs in Australia: 2002-2007. Pharma-coepidemiol Drug Saf 2010; 19: 82-89.
6. Zuliani V, Fantini M, Rivara M. Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. Curr Top Med Chem 2012; 12: 962-970.
7. Porter RJ. Addressing the need for new therapies for epilepsy. Epilepsia 2012; 53: 1840-1841.
8. Tate SK, Depondt C, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 2005; 102: 5507-5512.
9. Heinzen EL, Yoon W, Tate SK, Sen A, Wood NW, Sisodiya SM et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am J Hum Genet 2007; 80: 876-883.
10. Hung CC, Huang HC, Gao YH, Chang WL, Ho JL, Chiou MH et al. Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients. Pharmacogenomics 2012; 13: 1339-1349.
11. Manna I, Gambardella A, Bianchi A, Striano P, Tozzi R, Aguglia U et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 2011; 52: e40-e44.
12. Zimprich F, Stogmann E, Bonelli S, Baumgartner C, Mueller JC, Meitinger T et al. A functional polymorphism in the SCN1A gene is not associated with carbama-zepine dosages in Austrian patients with epilepsy. Epilepsia 2008; 49: 1108-1109.
13. Tate SK, Singh R, Hung CC, Tai JJ, Depondt C, Cavalleri GL et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics 2006; 16: 721-726.
14. Haerian BS, Baum L, Tan HJ, Kwan P, Raymond AA, Saruwatari J et al. SCN1A IVS5N +5 polymorphism and response to sodium valproate: a multicenter study. Pharmacogenomics 2012; 13: 1477-1485.
15. Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 2011; 18: 1159-1164.
16. Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino A, Valdizan EM et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 2010; 19: 93-101.
17. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br J Clin Pharmacol 2009; 68: 214-220.
18. Jang SY, Kim MK, Lee KR, Park MS, Kim BC, Cho KH et al. Gene-to-gene interaction between sodium channel-related genes in determining the risk of antiepileptic drug resistance. J Korean Med Sci 2009; 24: 62-68.
19. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Bri J Clin Pharmacol 2008; 66: 304-307.
20. Kwan P, Poon WS, Ng HK, Kang DE, Wong V, Ng PW et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 2008; 18: 989-998.
21. Tan NCK, Heron SE, Scheffer IE, Pelekanos JT, McMahon JM, Vears DF et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004; 63: 1090-1092.
22. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W et al. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on classification and terminology, 2005-2009. Epilepsia 2010; 51: 676-685.
23. Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, Harkin LA. SCN1A mutations and epilepsy. Hum Mutat 2005; 25: 535-534.
24. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
25. Nyholt D. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769.
26. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006; 38: 209-213.
27. Yang TP, Beazley C, Montgomery SB, Dimas AS, Gutierrez-Arcelus M, Stranger BE et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010; 26: 2474-2476.
28. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, Ingle CE et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet 2012; 8: e1002639.
29. Treatment of Epilepsy. Therapeutic Guidelines Ltd. eTG Complete, 2013. North Melbourne: Therapeutic Guidelines Ltd. Available from http://www.tg.org. au/.
30. Treatment of Epilepsy, Rossi S (ed). Australian Medicines Handbook [AMH]. S. Aust: Australian Medicines Handbook Pty Ltd: Adelaide; 2013.
31. Cockerell OC, Johnson AL, Sander JW, Shorvon SD. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997; 38: 31-46.
32. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62: 382-389.
33. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B et al. Defining early seizure outcomes in pediatric epilepsy: the good, the bad and the in-between. Epilepsy Res 2001; 43: 75-84.
34. Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998; 51: 1256-1262.
35. Zhang C, Wong V, Ng PW, Lui CH, Sin NC, Wong KS et al. Failure to detect association between polymorphisms of the sodium channel gene SCN1A and febrile seizures in Chinese patients with epilepsy. Epilepsia 2010; 51: 1878-1881.
36. Oterino A, Castillo J, Cayon A, Toriello M, Alonso A, Ruiz-Alegria C et al. Is the FHM3 gene SCN1A implicated in migraine? Cephalalgia 2007; 27: S577.